Drug intelligence / Profile preview

VOY-101

Development stage: Phase 2
Lead developer: Perceive Biotherapeutics
Modality: Gene Therapies
Administration: Intravitreal

Overview

VOY-101 is an investigational gene therapy developed by Perceive Biotherapeutics for the treatment of non-neovascular (dry) age-related macular degeneration (AMD), including geographic atrophy. It is administered as a single, unilateral intravitreal injection and is currently in Phase 1/2 clinical trials to assess safety and efficacy in patients with advanced AMD. The precise mechanism of action has not been disclosed or defined publicly, but it represents a novel approach within the field of eye disorder therapies[1][3][4][5][6].

Other names: VOY 101VOY101VOY-101

Beyond the preview

Go deeper on VOY-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VOY-101.

Explore the full profile